Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clomiphene citrate
Drug ID BADD_D00498
Description A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Indications and Usage Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation.
Marketing Status approved; investigational
ATC Code G03GB02
DrugBank ID DB00882
KEGG ID D00962
MeSH ID D002996
PubChem ID 60974
TTD Drug ID D0I5WB
NDC Product Code 51927-0249; 73377-229; 49884-701; 50090-0678; 10577-916; 46014-1122; 51927-0056; 0713-0885; 73212-029; 63629-2165; 63629-5302; 63275-9964; 63629-9276; 48087-0025; 49169-1040; 51552-1580; 68071-2638; 73309-047; 50090-6500; 17369-817; 48087-0144; 62991-2702; 61919-375; 38779-0390; 43647-456; 71052-338; 90027-025
UNII 1B8447E7YI
Synonyms Clomiphene | Clomifene | Chloramiphene | Clomifen | Clomiphene Citrate | Citrate, Clomiphene | Clomiphene Hydrochloride | Hydrochloride, Clomiphene | Serophene | Gravosan | Klostilbegit | Clostilbegit | Clomid | Clomide | Dyneric
Chemical Information
Molecular Formula C32H36ClNO8
CAS Registry Number 50-41-9
SMILES CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O) O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypospadias20.07.04.001; 03.03.01.005; 21.15.01.003--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Irritability08.01.03.011; 19.04.02.013--
Leukocytosis01.02.01.002--
Lung disorder22.02.07.001--Not Available
Lymphocytic leukaemia16.01.09.001; 01.10.09.001--Not Available
Macular oedema06.04.06.005--Not Available
Malignant melanoma23.08.01.001; 16.03.01.001--Not Available
Meningomyelocele17.19.01.006; 03.10.02.006--Not Available
Microcephaly15.11.02.002; 03.11.02.002--Not Available
Migraine17.14.02.001; 24.03.05.003--Not Available
Mood altered19.04.02.007--Not Available
Myalgia15.05.02.001--
Neurofibromatosis23.05.01.018; 17.18.01.002; 16.09.01.002; 03.10.01.002--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Optic neuritis06.04.08.002; 10.02.01.097; 17.04.05.001--Not Available
Ovarian cancer21.11.01.003; 16.12.04.001--Not Available
Ovarian cyst21.11.01.002; 16.04.03.001--Not Available
Ovarian enlargement21.11.02.001--Not Available
Ovarian germ cell teratoma benign16.04.03.002; 21.11.01.004--Not Available
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Patent ductus arteriosus03.07.01.001; 02.08.01.001; 24.03.03.002--Not Available
Phlebitis12.02.01.002; 24.12.03.004--
Photophobia17.17.02.006; 06.01.01.004--
Photopsia17.17.01.006; 06.02.06.004--
Pituitary tumour16.24.01.003; 05.03.05.002--Not Available
Plasma cell myeloma01.14.02.004; 16.23.02.004--Not Available
Pollakiuria20.02.02.007--
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages